Shop by goal
Popular compounds
Research resources
Recently viewed
PRECISION. PURITY. PERFORMANCE.
Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.
Shop
Research
Support
Ways to Pay
Shop by goal
Shop by compound
Shop by region
Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.
All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.
Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.
© 2026 New-U Research Compounds · new-u.io
BPC+TB 5mg Combo
Choose pack size
Select strength and vial count — prices shown for the selected SKU
Lab-direct quality — full packs or single-vial samples
Every batch ships straight from the lab that synthesises it — sealed, tamper-evident, and HPLC-verified to >99% purity . Buying direct means you pay the lab-direct rate on every vial, with nothing stacked on top.
Order a full sealed 10-vial research pack for a complete study supply, or add a single-vial sample alongside your pack to trial a new compound first. Same lab, same batch, same verified purity — scaled to whatever your research needs.
What It's Researched For
In plain terms, this is the two best-known repair peptides in one vial. Here is what that looks like across the research.
Tissue-repair research
BPC-157 and TB-500 dominate the published peptide repair literature and are almost always studied together.
Angiogenesis
BPC-157 is studied for blood-vessel formation signalling, notably through the VEGFR2 pathway.
Cell migration
TB-500 works through a different route — binding actin monomers, which is central to how cells move into a repair site.
Fewer handling steps
One vial and one reconstitution rather than two separate lyophilised powders.
Overview
In short: A fixed two-compound research blend of BPC-157 and TB-500 at 5 mg each — 10 mg of total peptide per vial, combining the two most-studied tissue-repair peptides.
Key research facts
Research use only. These points summarise lab themes, not human outcomes.
If you look at the published research on peptides and tissue repair, two compounds account for most of it: BPC-157 and TB-500. They appear together constantly — not because anyone has shown they work better in combination, but because they address the same research questions from different mechanistic angles. This blend supplies both at 5 mg per vial, for 10 mg of total peptide.
BPC-157 is a synthetic pentadecapeptide (GEPPPGKPADDAGLV) derived from a sequence in human gastric juice. Its stability in gastric conditions is unusual for a peptide and is part of why it attracted attention. The research focus is angiogenic signalling — the formation of new blood vessels — with VEGFR2 pathway activation the most-cited mechanism. TB-500 comes at repair differently: it is the synthetic analogue of the actin-binding domain of thymosin beta-4, and it is studied for actin monomer sequestration and the cell migration that depends on it.
The blend has no literature of its own. No pharmacokinetic or efficacy study has examined the two administered as a fixed combination, and sharing a vial does not merge their clearance profiles. Treat it as a handling convenience over two separate compounds. Supplied as research-grade lyophilised powder for in-vitro and preclinical work only; nothing on this page is medical advice.
Mechanism of Action
The blend has no combined mechanism — it is two independent compounds sharing a vial. BPC-157 is studied for angiogenic signalling through VEGFR2, TB-500 for actin monomer binding and cell migration. The mechanisms are distinct and the research domains overlap.
The two compounds are studied together so routinely that the combination can look like an established formulation, but it is not. No controlled study has characterised BPC-157 and TB-500 administered as a fixed blend — no combined pharmacokinetics, no interaction data, no evidence for or against additive or synergistic behaviour. Their individual literatures are also weaker than their popularity suggests: both are predominantly rodent, neither has controlled human efficacy data, and BPC-157 was reviewed by the FDA Pharmacy Compounding Advisory Committee in July 2026 for 503A Bulks List eligibility — a compounding review, not an approval. One practical asymmetry matters for protocol design: the animal literature commonly describes TB-500 with a longer effective window than BPC-157, which is why component schedules often differ in frequency. A fixed blend forces a single frequency on both.
Common Questions People Are Asking
What is in the BPC+TB 5mg Combo?
Each vial contains BPC-157 5 mg and TB-500 5 mg — 10 mg of total peptide, in a fixed 1:1 ratio across every vial in the pack. Both components are also available individually, so the blend can be benchmarked against its parts. It is supplied for laboratory research only and is not for human use.
How does this differ from the 10mg combo?
Only in strength. The BPC+TB 10mg Combo contains BPC-157 10 mg and TB-500 10 mg per vial — 20 mg total, double this one, at the same 1:1 ratio. The compounds and the ratio are identical; the higher-strength vial simply carries more of each per reconstitution.
Do BPC-157 and TB-500 work better together?
No study has shown that. They are combined because their research domains overlap, not because synergy has been demonstrated — no pharmacokinetic, interaction or comparative efficacy data exists for the pair administered together. Their mechanisms are genuinely distinct: angiogenic signalling for BPC-157, actin binding for TB-500.
Is a fixed blend a disadvantage for protocol design?
It can be. The animal literature commonly describes TB-500 with a longer effective window than BPC-157, so component protocols often use different frequencies. A fixed blend forces a single administration frequency on both. If that matters for a given research design, the separate compounds give more control.
How should the combo be stored?
Keep the lyophilised powder frozen at −20 °C. After reconstitution with bacteriostatic water or sterile saline, refrigerate at 1–6 °C and protect from light. Because the vial contains two compounds with different stability characteristics, use it within the validated window for the batch rather than extrapolating from either component alone.
Where can I buy BPC+TB 5mg Combo?
Right here — BPC+TB 5mg Combo is supplied directly by New-U Research Compounds on this page. Every batch is independently third-party tested to >99% HPLC purity with a batch-linked Certificate of Analysis, supplied as lyophilised research-grade material, and shipped direct from source worldwide in discreet, tracked packaging. Strictly for laboratory research use only — not for human use.
How much does BPC+TB 5mg Combo cost?
BPC+TB 5mg Combo pricing is shown live on this page, per pack size — 10-vial research packs as standard, with single-vial sample options on selected compounds. Larger vial strengths lower the per-mg cost, every order includes the batch Certificate of Analysis, and shipping is free on orders over $300.
Is BPC+TB 5mg Combo third-party tested?
Yes. Every BPC+TB 5mg Combo batch is verified by independent laboratories (Janoshik Analytics and Freedom Diagnostics) for identity and purity, with a batch-linked Certificate of Analysis confirming >99% purity by HPLC. Every order ships with its COA, and current batch certificates are published on our COA page.
How do I buy BPC+TB 5mg Combo?
Add the BPC+TB 5mg Combo pack size you need to your cart and check out: enter your shipping details, then choose your payment method — cryptocurrency or card — on the next step. Every order ships with its batch Certificate of Analysis (COA). BPC+TB 5mg Combo is supplied strictly for laboratory research use only, not for human or veterinary use.
What payment methods can I use to buy BPC+TB 5mg Combo?
At checkout you can pay by cryptocurrency (BTC, ETH, SOL, LTC, USDC, USDT and more) or by card, each handled by a dedicated secure payment provider. You choose your method after confirming your order.
How fast is shipping, and do you ship worldwide?
Yes — we ship worldwide in discreet, unmarked, temperature-stable, tracked packaging. Delivery typically takes 6–14 business days, and shipping is free on orders over $300.
Is it legal to buy BPC+TB 5mg Combo?
In the United States, BPC+TB 5mg Combo is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction — buyers are responsible for compliance in their own region.
Pharmacokinetics
Evidence Tier
Overall: Tier 3: Anecdotal / self-report
The blend itself has no evidence base: no pharmacokinetic, safety or efficacy study has examined BPC-157 and TB-500 administered together as a fixed combination, and no interaction data exists. Both components have substantial but predominantly rodent literatures with no controlled human efficacy data. Neither has regulatory approval — BPC-157's July 2026 FDA compounding-committee review concerned 503A Bulks List eligibility, which is not an approval. Supplied as unapproved laboratory material.
Source References & Further Reading
Last reviewed: 29 July 2026 · New-U Research Compounds
Key Characteristics
Specifications
About the BPC+TB Combo: BPC-157 and TB-500 Research Blend Guide
BPC-157 and TB-500 are the two compounds most people encounter first in peptide tissue-repair research, and they are studied together so consistently that a pre-combined vial is a reasonable supply format. This blend provides 5 mg of each — 10 mg of total peptide per vial — removing one weighing and reconstitution step from a two-compound protocol.
The two work differently. BPC-157 is a pentadecapeptide derived from a gastric protective sequence, notable for unusual stability in gastric conditions, and studied principally for angiogenic signalling through the VEGFR2 pathway. TB-500 is the synthetic analogue of the actin-binding domain of thymosin beta-4 and is studied for actin monomer sequestration and the cell migration that depends on it. Distinct mechanisms, overlapping research questions — which is precisely why they appear together.
It is worth being clear about the evidence. Both compounds have large literatures, but those literatures are predominantly rodent and neither has controlled human efficacy data. BPC-157 was among the peptides reviewed by the FDA Pharmacy Compounding Advisory Committee in July 2026 for potential 503A Bulks List inclusion — a compounding-eligibility discussion, not an approval. And the combination itself has been studied by nobody: no combined pharmacokinetics, no interaction data. New-U Research Compounds supplies this blend as research-grade lyophilised powder with a batch certificate of analysis, strictly for in-vitro and preclinical research use. It is not approved for human therapeutic use in any jurisdiction, and nothing on this page constitutes medical advice or a dosing recommendation.
Customer Reviews
No customer reviews yet — be the first to share your experience.
More in Stacks
BPC+TB 5mg Combo vs related Stacks compounds
Descriptive catalog comparison for research sourcing decisions — not dosing guidance. All compounds are for laboratory research use only.